# Matthew J. Ellis

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/matthew-j-ellis/

## Facts

| Field | Value |
| --- | --- |
| Citations | 67,117 |
| Field | Advanced Breast Cancer Therapies |
| h-index | 111 |
| i10-index | 325 |
| Last Known Institution | Guardant (United States) |
| OpenAlex ID | https://openalex.org/A5057135409 |
| ORCID iD | https://orcid.org/0000-0002-8467-8534 |
| Works | 1,078 |

## Researcher papers

- [Proteogenomics connects somatic mutations to signalling in breast cancer](https://scholariq.org/papers/proteogenomics-connects-somatic-mutations-to-signalling-in-breast-cancer/)
- [The molecular portraits of breast tumors are conserved across microarray platforms](https://scholariq.org/papers/the-molecular-portraits-of-breast-tumors-are-conserved-across-microarray/)
- [Whole-genome analysis informs breast cancer response to aromatase inhibition](https://scholariq.org/papers/whole-genome-analysis-informs-breast-cancer-response-to-aromatase-inhibition/)
- [Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group](https://scholariq.org/papers/assessment-of-ki67-in-breast-cancer-updated-recommendations-from-the/)
- [Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer](https://scholariq.org/papers/adjuvant-paclitaxel-and-trastuzumab-for-node-negative-her2-positive-breast/)
- [Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study](https://scholariq.org/papers/preoperative-treatment-of-postmenopausal-breast-cancer-patients-with-letrozole-a/)
- [Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas](https://scholariq.org/papers/phase-i-safety-pharmacokinetics-and-clinical-activity-study-of-lapatinib/)
- [Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031](https://scholariq.org/papers/randomized-phase-ii-neoadjuvant-comparison-between-letrozole-anastrozole-and/)
- [Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial](https://scholariq.org/papers/pictilisib-for-oestrogen-receptor-positive-aromatase-inhibitor-resistant/)
- [Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models](https://scholariq.org/papers/targeting-chk1-in-p53-deficient-triple-negative-breast-cancer-is-therapeutically/)

## Researcher topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Guardant (United States)](https://scholariq.org/institutions/guardant-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.